Target intelligence / Profile preview

FKBP12 F36V (mutant form of FKBP12, FK506-binding protein 1A) (FKBP12¹F36V (or FKBP12(F36V)))

Target
FKBP12¹F36V (or FKBP12(F36V))
Molecular classification
Enzyme, peptidyl-prolyl cis-trans isomerase, PPIase
01

Overview

FKBP12 F36V is an engineered point mutant (phenylalanine 36 to valine) of the human FKBP12 protein (FK506-binding protein 1A, a 12 kDa peptidyl-prolyl isomerase). The F36V substitution creates a hydrophobic specificity pocket that enables high-affinity binding (low/sub-nanomolar) to synthetic ligands with "bump" substituents, which do not bind wild-type FKBP12. This mutant is widely used as a fusion tag in chemical biology for rapid, selective control of tagged proteins, including degradation via PROTAC/dTAG systems (recruiting CRBN or VHL E3 ligases), fluorescent labeling in live cells, stabilization of destabilizing domains (e.g., with Shield-1/2), and inducible dimerization (e.g., AP1903 for apoptosis in gene therapy). It supports applications in target validation for oncoproteins like KRASG12V, BRD4, and EWS/FLI, with degradation often occurring within 1 hour

Other names
F36V-FKBPFKBP12¹WT (distinguished from wild-type)FKBP(F36V)FKBP*
02

Mechanism of action

Recruitment of E3 ubiquitin ligases (CRBN or VHL) for targeted protein degradation (in dTAG system); Stabilizing ligand binding to prevent proteasomal degradation (in destabilizing domains); Fluorescent labeling for imaging; Dimerization for signaling activation (e.g., apoptosis induction)

03

Biological functions

Protein folding (chaperone activity)Protein stability regulation (in destabilizing domain systems)Ligand-induced heterodimerization (for degradation or labeling)
04

Safety considerations

Hook effect at high doses (reduced degradation efficacy)Potential off-target engagement with wild-type FKBP12 for some ligands (e.g., meta-substituted dTAGs)Context-specific degradation efficiency varies by fusion partner and cell type
05

Interacting drugs

dTAG-7

9 more in the full profile.

Beyond the preview

Go deeper on FKBP12 F36V (mutant form of FKBP12, FK506-binding protein 1A) (FKBP12¹F36V (or FKBP12(F36V))).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FKBP12 F36V (mutant form of FKBP12, FK506-binding protein 1A) (FKBP12¹F36V (or FKBP12(F36V))).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call